The market revenue for North America’s oligonucleotide CDMO sector continues its robust upward trajectory. In 2025, the revenue is projected to reach 2,450 Million USD, compared to 1,220 Million USD in 2020. The market is expected to surpass 7,200 Million USD by 2035, driven by a steady CAGR exceeding 11%. This acceleration is largely due to the expansion of gene and cell therapies, rising personalized medicine programs, and increasing collaborations between CDMOs and drug developers. Adoption of advanced synthesis technologies and an uptick in regulatory approvals for oligonucleotide drugs will continue to underpin growth across the forecast period.
Read More - https://bussinessinsights.com/research-report/north-america-oligonucleotide-cdmo-market
In 2025, diagnostics remain the leading application for oligonucleotide CDMOs in North America, making up over one-third of total demand. This is largely attributed to expanding molecular diagnostics for infectious disease and oncology. The therapeutics segment, closely following diagnostics, is fueled by ongoing innovation in RNA, antisense, and gene-editing drugs. Research applications (academic and commercial labs) also contribute substantially as high-throughput genetic analysis becomes standard across fields. The forensics sector, though smaller, is experiencing interest due to advanced DNA profiling techniques in legal and security domains. This distribution underscores the versatility of oligonucleotides and the sector’s responsiveness to medical and scientific advancements.
Request Free Sample- https://bussinessinsights.com/request/healthcare/north-america-oligonucleotide-cdmo-market
Who are the key players in North America Oligonucleotide CDMO Market industry?
The top five key players in the North America Oligonucleotide CDMO market are Thermo Fisher Scientific, Agilent Technologies, Bio-Synthesis Inc., LGC Biosearch Technologies, and Genscript Biotech. These companies provide custom oligonucleotide synthesis, development, and manufacturing services for pharmaceutical and biotechnology sectors, supporting research and therapeutic innovations.
What is the North America Oligonucleotide CDMO Market growth?
The North America Oligonucleotide CDMO market is experiencing robust growth, with a CAGR of over 10% from 2023 to 2028. This surge is attributed to increased investment in gene therapies and nucleic acid-based drugs, notably supported by Thermo Fisher Scientific's expansion in oligonucleotide manufacturing capabilities.
Which segment accounted for the largest North America Oligonucleotide CDMO Market share?
The therapeutics segment holds the largest market share in the North America Oligonucleotide CDMO market. Rising development of oligonucleotide-based drugs for conditions such as cancer and rare diseases, and growing FDA approvals, drive demand for CDMO services focused on clinical and commercial therapeutic production.
Thanks & Regards,
Manisha C
sales [at] bussinessinsights.com